CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a research report released on Friday morning. The firm issued a sell rating on the stock.

CEL-SCI Stock Performance

CEL-SCI stock opened at $0.26 on Friday. The firm has a 50-day moving average of $0.37 and a 200-day moving average of $0.66. CEL-SCI has a 1-year low of $0.25 and a 1-year high of $2.39. The firm has a market cap of $20.08 million, a P/E ratio of -0.54 and a beta of 0.67. The company has a current ratio of 1.07, a quick ratio of 1.09 and a debt-to-equity ratio of 0.66.

Institutional Trading of CEL-SCI

Several institutional investors have recently added to or reduced their stakes in CVM. Plotkin Financial Advisors LLC purchased a new position in shares of CEL-SCI in the third quarter worth approximately $98,000. Thoroughbred Financial Services LLC boosted its stake in shares of CEL-SCI by 40.1% during the 4th quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after acquiring an additional 54,900 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of CEL-SCI by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after acquiring an additional 53,879 shares during the period. 12.08% of the stock is currently owned by hedge funds and other institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.